Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of 800 mg MSI-195 in
reducing symptoms of depression in Major Depressive Disorder (MDD)patients with inadequate
response to current antidepressant therapy.